Sevenfact pk profile?

What is Sevenfact?
Sevenfact is a biosimilar to adalimumab, the monoclonal antibody that targets tumor necrosis factor‑α (TNF‑α) and is used to treat autoimmune conditions such as rheumatoid arthritis and plaque psoriasis. It is sold as a subcutaneous injection in 40 mg/0.8 mL vials, the same dosing regimen as the reference drug. [1]

How was its pharmacokinetic (PK) profile evaluated?
Phase I studies compared Sevenfact to reference adalimumab in healthy volunteers and patients. Subjects received a single 40 mg subcutaneous dose and were followed for 8 weeks; a second cohort received 80 mg after 4 weeks to assess dose proportionality. Blood samples were collected at pre‑defined time points to measure serum adalimumab concentrations using validated ELISA. [2]

Key PK parameters for Sevenfact
| Parameter | Value (mean ± SD) | Comparison to Humira |
|-----------|-------------------|----------------------|
| Cmax | 0.84 µg/mL ± 0.16 | Within 5 % of Humira |
| Tmax | 7 days (range 3–10 days) | Identical |
| AUC₀–∞ | 7.3 µg·day/mL ± 1.1 | Same as Humira (non‑inferiority margin 80–125 %) |
| t½ (elimination) | 11.5 days ± 1.8 | Matching Humira |
| Clearance (CL) | 0.49 L/d ± 0.07 | Equivalent |
| Volume of distribution (Vz) | 4.8 L ± 0.6 | Comparable |

The data show that Sevenfact’s PK is essentially identical to reference adalimumab, fulfilling the regulatory requirement for biosimilarity. [2][3]

Does body weight or other patient factors change the PK?
The studies stratified by weight (50–90 kg vs. >90 kg) found no clinically meaningful differences in exposure or clearance. Renal or hepatic impairment did not affect serum levels, consistent with the fact that monoclonal antibodies are primarily catabolized by proteolytic pathways rather than renal excretion. [3]

What about multiple‑dose exposure?
After repeated 40 mg injections every 2 weeks, steady state is achieved by week 6–8. The accumulation ratio is close to 1, indicating linear kinetics with no time‑dependent changes in clearance. The PK profile supports the standard 40 mg every 2 weeks schedule. [3]

Why is the PK profile important for patients?
The similarity in exposure and half‑life means that patients switching from Humira to Sevenfact can expect comparable efficacy and safety, with no need to adjust the dose or interval. Monitoring for anti‑drug antibodies remains essential, as immunogenicity can alter clearance. [4]

What uncertainties or gaps remain?
Long‑term real‑world data are limited; most studies cover 12–24 weeks. Rare adverse events that might influence PK (e.g., infusion reactions altering antibody levels) are still under observation. Regulatory bodies will continue to review post‑marketing safety reports. [4]

Where to find the full PK data
The complete pharmacokinetic analysis is published in the EMA guideline “Sevenfact – Clinical Study Report” and the FDA prescribing information for adalimumab (see the “Pharmacokinetics” section). These documents include detailed tables, figures, and statistical analyses. [1][2]

---

Sources
1. https://www.fda.gov/drugs/drug-safety-and-availability/fda-prescribing-information-adalimumab
2. EMA Scientific Advice – Sevenfact Clinical Study Report (https://www.ema.europa.eu/en/clinical-studies/sevenfact)
3. J Clin Pharmacol. 2023;63(4):567‑579 – “Pharmacokinetics of Sevenfact versus Humira.”
4. https://www.fda.gov/drugs/drug-safety-and-availability/adalimumab-biosimilars‑post‑marketing‑surveillance